Percutaneous Renal Biopsy

Louis-Philippe Laurin, Alain Bonnardeaux, Michel Dubé and Martine Leblanc
University of Montreal
Canada

1. Introduction

Renal biopsy is an essential tool for the diagnosis of several renal diseases. The first renal biopsies were performed in 1923 as open surgical procedures (Gwyn, 1923). The percutaneous approach has been part of the clinical practice since 1951 (Iversen & Brun, 1951). A few years later, a description of the procedure with the patient placed in a prone position was published (Kark & Muehrcke, 1954). The new technique had a success rate of more than 90% and was not associated with major complications. Percutaneous ultrasound-guided renal biopsy is now considered as the standard method. It is a routine procedure that can be done with minimal discomfort to the patient. Here we review major topics related to this frequent and useful procedure in the field of nephrology.

2. Indications

Although indications for renal biopsy can sometimes be a matter of debate among nephrologists, common indications include: isolated hematuria, mild to moderate proteinuria, nephrotic syndrome, glomerulonephritis, acute renal failure, renal manifestations of systemic diseases and chronic renal failure (Table 1). There is also an important role for percutaneous kidney biopsy in kidney transplantation. Percutaneous kidney biopsy is not only reserved for the diagnosis of renal parenchymal diseases, but it may also have a role in the diagnosis of renal tumor as described below in this chapter. Impacts of diagnosis made by kidney biopsy have to take into account considerations beyond therapeutic implications. A kidney disease diagnosis within the patient’s records could have psychological and financial consequences (e.g. insurances), and can modify family planning decisions (e.g. hereditary renal diseases) (Korbet, 2002). Performing a percutaneous kidney biopsy therefore implies a good communication between the attending physician and his patient.

3. Contraindications

In 1988, the Health and Public Policy Committee of American College of Physicians (ACP) elaborated a list of contraindications to kidney biopsy (ACP, 1988). As described below, the relevance of this policy may be actually questioned upon recent technological developments resulting in a virtual absence of catastrophic complications in recent series (Waldo et al., 2009).
3.1 Absolute contraindications

Several contraindications to renal biopsy have been described (Madaio, 1990). Absolute contraindications are generally recognized as uncontrolled bleeding diathesis, anatomic abnormalities, uncooperative behaviour and pregnancy (Table 1). Chronic renal disease associated with two small kidneys with cortical atrophy remains a contraindication to renal biopsy, since the bleeding risk is high, but can be considered relative if performed by a well-experienced operator. Absence of an appropriate pathologic support makes no sense to perform a biopsy and should therefore be considered as a contraindication (Korbet, 2002). Single functioning kidney is not considered as an absolute contraindication anymore because of technical and real-time imaging improvements over the last decades. As stated in a report of nine cases of normal size solitary kidney biopsy, it can be performed with good outcomes in terms of bleeding and renal function (Mendelssohn & Cole, 1995). In this series, the only complication reported was post-procedure gross hematuria in one patient. Histopathological diagnosis was made in eight of nine cases.

One can argue that an uncooperative patient is no longer an absolute contraindication in particular circumstances. Intensive care unit patients on mechanical ventilation appear to tolerate well bedside biopsy with appropriate administration of sedative agents (Conlon et al., 1995). The procedure is performed off ventilator with ventilation controlled with an ambu bag, permitting a perfect synchronization between respiratory movements and needle insertion, thereby minimizing risks of complications.

3.2 Relative contraindications

Relative contraindications consist in conditions that may be reversed, sometimes relatively easily; these include uncontrolled hypertension or hypotension, renal abscesses, pyelonephritis, hydronephrosis, marked obesity, severe anemia, previous technical failure, uremia, anatomic abnormalities of kidney such as large renal tumors, arterial aneurysm and cysts (Table 1) (Madaio, 1990). Correction of these medical conditions with antihypertensive medication, antibiotics or blood transfusions makes possible the biopsy to be carried out safely.

4. Preparation

First, the patient’s past medical history information should be reviewed before the biopsy. Personal and family history of bleeding diathesis, and allergy to substances used during the procedure such as povidone-iodine should be evaluated. Second, a thorough physical examination should be undertaken to look for skin infection as well as anatomic anomalies (e.g. obesity) that could interfere with the procedure. An assessment of blood pressure control is also essential.

A pre-biopsy laboratory evaluation is also made routinely and includes complete biochemical profile, complete blood count and urinalysis. Baseline coagulation parameters, including platelet count, prothrombin time, partial thromboplastin time and fibrinogen, are usually documented before biopsy procedure. Bleeding time is also commonly analyzed prior to the biopsy, but its role to predict post-biopsy bleeding remains controversial; it will be discussed in detail later in this chapter. Stopping all the medications that could disrupt normal coagulation should normally prevent post-procedural bleeding. Antiplatelet agents and non-steroidal anti-inflammatory drugs have to be withdrawn prior to the procedure for at least seven days. Performing a renal biopsy in patients on anticoagulation therapy is
always a medical challenge. Decision to stop the anticoagulants before the biopsy should be based on the patient’s thromboembolism risks. If the decision is made to do the biopsy, an anticoagulation bridge with intravenous anticoagulation (e.g. heparin) is needed in most cases.

A good preparation is an essential step to minimize the risk of bleeding complications as well as to intervene promptly in case of an adverse event.

<table>
<thead>
<tr>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isolated hematuria</td>
<td>Relative</td>
</tr>
<tr>
<td>Mild to moderate proteinuria</td>
<td>Uncontrolled hypertension</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Nephritic syndrome</td>
<td>Renal abscesses</td>
</tr>
<tr>
<td>Glomerulonephritis suspicion</td>
<td>Pyelonephritis</td>
</tr>
<tr>
<td>Renal manifestations of systemic diseases</td>
<td>Hydronephrosis</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>Marked obesity</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>Severe anemia</td>
</tr>
<tr>
<td>Renal tumor in selected patients</td>
<td>Uremia</td>
</tr>
<tr>
<td></td>
<td>Large renal tumors or cysts</td>
</tr>
<tr>
<td></td>
<td>Solitary kidney</td>
</tr>
<tr>
<td></td>
<td>Previous technical failure</td>
</tr>
<tr>
<td></td>
<td>Atrophic kidney(s)</td>
</tr>
<tr>
<td>Absolute</td>
<td>Bleeding diathesis</td>
</tr>
<tr>
<td></td>
<td>Anatomic abnormalities</td>
</tr>
<tr>
<td></td>
<td>Uncooperative behavior</td>
</tr>
<tr>
<td></td>
<td>Pregnancy</td>
</tr>
</tbody>
</table>

Table 1. Indications and contraindications of kidney biopsy

5. Procedure

As mentioned earlier, percutaneous renal biopsy under ultrasound guidance is now the gold standard method to obtain renal tissue for the diagnosis of renal diseases. It is generally considered superior to other techniques because of its numerous advantages: it allows continuous visualization of both kidney and needle, can be done regardless of the renal function, avoids exposure to radiation, permits procedure to be performed at bedside and avoids the administration of nephrotoxic contrast media (Korbet, 2002). Several other biopsy techniques exist, such as laparoscopic, computed tomography (CT)-guided and transjugular renal biopsy. Here, we will focus mainly on ultrasound-guided techniques.

An adequate tissue sample (Figure 1) permitting an accurate diagnosis of a glomerular disease with light microscopy usually contains 8 to 10 glomeruli. It must include juxtamedullary glomeruli due to their preferential involvement in focal segmental glomerulosclerosis. In these focal lesions, at least 25 glomeruli may be required to have greater than 95% chance of finding evidence of such renal injury (Fogo, 2003).

In 1988, the American College of Physicians (ACP) stated the minimal requirements (Table 2) that a nephrology fellow must acquire to perform percutaneous renal biopsy safely (ACP, 1988). It is interesting to note that in a recent survey among 133 nephrology trainees, 75.3%
of them reported that they had little or no training, or some training but not enough to feel competent in doing renal biopsy independently (Berns, 2010).

**Skills**

**Cognitive skills**

Knowledge of:
- Indications and contraindications
- When to use open renal biopsy
- Renal and surrounding anatomy
- Technique to use and position of the biopsy needle
- Examining and handling tissue for histologic processing
- Complications and how to detect and treat them
- Medications required for the procedure
- Role of the biopsy in determining treatment
- Alternatives to the procedure

Ability to:
- Provide medical monitoring and intervention
- Communicate the risks, benefits, and results to the patient for purposes of informed consent

**Technical skills**

Ability to:
- Choose appropriate biopsy needle
- Use appropriate techniques to localize the kidney
- Appropriately place biopsy needle and obtain tissue

Table 2. Skills related to percutaneous renal biopsy (from ACP, 1988)

The patient should provide an informed consent before the procedure. No oral intake is usually permitted after midnight on the day of the procedure, except for a light meal if the procedure is planned late in the morning or early in the afternoon. A well-trained nephrologist or radiologist at the radiology department, or at bedside if needed, usually performs the procedure. An intravenous access is placed to insure adequate hydration. Vital signs have to be monitored throughout the procedure.

Kidney biopsies are usually performed with the patient in prone position, after the skin is properly disinfected and draped. This position provides the most rational approach to a retroperitoneal organ. It also brings the kidney closer to the posterior abdominal wall. Local anesthesia is usually carried out with lidocaine. Tissue biopsies are acquired from the lower pole of the kidney, next to the renal capsule, with the left kidney usually preferred for ergonomic reasons. The operator must be aware that subcapsular cortical samples have overrepresentation of sclerosis related to hypertension, aging and non-specific scarring (Fogo, 2003). Samples are obtained when the patient is holding his breath. One or two needle passes are routinely performed.

Another approach, commonly used to perform liver biopsy, is the transjugular renal biopsy. This technique is usually performed in academic centers by well-trained interventional physicians (nephrologists or radiologists) and should be reserved for high-risk patients with contraindications to percutaneous renal biopsy such as liver disease, bleeding diathesis and obesity. The main disadvantage of this technique is lower diagnostic yield, mainly because
medulla needs to be traversed first before reaching the renal cortex. A recent retrospective study showed a good safety and efficacy of transjugular renal biopsy in 23 high-risk patients (Sarabu et al., 2010). An adequate tissue for histopathological diagnosis was obtained in 87% of patients. Three patients (13%) experienced bleeding requiring blood transfusion. Neither deaths nor embolization/nephrectomy were reported.

A supine antero-lateral position (SALP) for percutaneous biopsy has been suggested recently (Gesualdo et al., 2008). It can be an interesting and useful alternative to the prone position for obese patients. This technique is also less invasive than a transjugular biopsy, and certainly provides a better diagnostic yield due to a direct access to the distal cortex. High-risk patients with a BMI >30 and/or respiratory difficulty underwent a SALP biopsy and were compared with low-risk (BMI ≤30 and/or no respiratory difficulty) patients receiving ultrasound-guided renal biopsy in either the prone position or SALP, for a total of 110 patients. There were a significantly better comfort compliance and less breathing difficulties for SALP patients. Post-procedure bleeding complications were minor in all three groups. The authors concluded that SALP may therefore be considered seriously for patients who otherwise would have been submitted to more invasive procedure.

5.1 Optimal depth
Pasquariello and colleagues (Pasquariello et al., 2007) published a novel approach to calculate the optimal depth needed to decrease significantly hemorrhagic complications, as well as tissue sample inadequacy. All 126 percutaneous native kidney biopsies, using a 14-gauge automated biopsy gun under sonographic guidance, were performed with optimal depth previously calculated. Adequacy rate of specimens for diagnosis and complication rate were compared with retrospective data obtained for 123 biopsies. Incidence of bleeding complications was significantly reduced using the theoretical calculation of optimal depth, together with an adequate sampling permitting an accurate diagnostic evaluation from renal tissue. Depth where pushing the trigger was calculated by a mathematical formula defined below (1).

\[
\text{Optimal depth} = \frac{\text{BW}}{H^{0.5}}
\]

(1)

BW represents the body weight expressed in hectograms and H the height expressed in centimeters.

5.2 Real-time versus blind ultrasound
Biopsy procedure can be performed under real-time or blind ultrasound-guided technique. Real-time method implies continuous visualization of the kidney for exact localization of the biopsy site (Figure 2). Blind method requires a sonographic localization of the kidney only before needle insertion. A proper needle placement is thereafter assessed by appropriate tissue resistance and observation of the respiratory excursion of the needle. A study by Maya and colleagues (Maya et al., 2007) showed that real-time ultrasound-guided technique provided a superior yield of kidney tissue and resulted in fewer bleeding complications. This retrospective study of 129 patients showed a higher mean number of glomeruli per biopsy in the sonographic-guided group compared to the blind biopsy group (18 ± 9 versus 11 ± 9), and fewer large hematomas requiring intervention (0% versus 11%).
5.3 Outpatient observation versus hospitalization

The low occurrence rate of bleeding complications with percutaneous kidney biopsies performed under real-time ultrasound led to elective procedures in an outpatient setting using standardized protocols. Overnight hospitalization would not be therefore needed, reducing the overall cost of elective renal biopsies.

A recent study by Maya and Allon (Maya & Allon, 2009) confirmed the safety and effectiveness of such an approach. During a 20-month period, 100 patients underwent a
percutaneous renal biopsy under real-time ultrasound guidance with a 16-gauge spring-loaded biopsy gun. A majority of patients (91%) required only one or two needle passes, reflecting the technical advantage of the real-time ultrasound guidance. A color Doppler ultrasound was performed immediately after the procedure to exclude active bleeding. In this series, no patient experienced serious complications related to the biopsy. Only four patients were hospitalized because of an >4% decrease in their hematocrit. Neither blood transfusion nor selective embolization was needed for these patients. Nonetheless, one can argue that such an approach should be reserved for highly selected patients who do not need urgent renal biopsy in the setting of acute kidney injury or bleeding disorders. Common sense should therefore prevail regarding the decision to hospitalize or not a patient after biopsy. It is mainly an institution-based decision. At our hospital, we prefer to hospitalized all patients overnight after the biopsy.

6. Needle

Several types of needles have been used during medical history to perform percutaneous renal biopsy. In 1951, Iversen and Brun (Iversen & Brun, 1951) described a percutaneous native kidney biopsy technique using an aspiration needle. Later, Kark and Muehrcke (Kark & Muehrcke, 1954) published a technique whereby cutting needles were employed, such as the Franklin-Vim-Silverman and the Tru-Cut (Baxter, Deerfield, IL) needles. The automated biopsy-gun (Figure 3) became popular in the nineties based on its potential benefits in reducing bleeding complications, for shorter actual time the needle resides in the kidney, and the fact that it requires less dexterity by the operator (Madaio, 1990). A randomized prospective trial comparing the two methods showed adequate tissue sampling, but the extent of bleeding was more severe in the free-hand biopsy group (D. Kim et al., 1998).

Fig. 3. Automated biopsy-gun
A number of different needle sizes are available for percutaneous biopsy techniques, ranging from 14 to 18 gauge (G). Needle gauge has a huge impact on the sample obtained. Eighteen- or 19-G needles are often unable to give a good specimen, and provide inadequate representation of vessels. In past years, there were concerns in the literature regarding bleeding risk with the use of larger needles. However, recent data (Tung et al., 1992; Song & Cronan, 1998; Nicholson et al., 2000; Manno et al., 2004) refuted such beliefs by showing that larger gauge needles provided better adequacy in tissue sampling and were not associated with higher complication rates. More specifically, a study (Nicholson et al., 2000) comparing 14, 16, and 18-G needles in renal transplants demonstrated an improved diagnostic value with increased needle size and no significant difference in macroscopic hematuria between the three groups. Nevertheless, the use of 14-G needle may create more pain. Overall, utilization of 16 G needle appears to be the best compromise between patient comfort and histopathological diagnostic yield.

7. Complications

Complications associated with percutaneous renal biopsy can be categorized as minor (gross hematuria and silent hematoma), major (hematoma requiring transfusion and/or embolization) or catastrophic (loss of functional mass and death) (Mendelsohn & Cole, 1995). Percutaneous renal biopsies using aspiration technique were associated with severe complications, mainly hemorrhage, with mortality rates of nearly 0.07% in large series reported in the fifties (Schwarz et al., 2005).

<table>
<thead>
<tr>
<th>Complications</th>
<th>Rate of occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minor</strong></td>
<td></td>
</tr>
<tr>
<td>Gross hematuria</td>
<td>0 to 6% (Maya et al. 2009)</td>
</tr>
<tr>
<td>Silent hematoma</td>
<td>33.3% (Manno et al. 2004)</td>
</tr>
<tr>
<td><strong>Major</strong></td>
<td></td>
</tr>
<tr>
<td>Hematoma requiring transfusion and/or embolization</td>
<td>1.2 % (Manno et al. 2004)</td>
</tr>
<tr>
<td><strong>Catastrophic</strong></td>
<td></td>
</tr>
<tr>
<td>Loss of functional mass</td>
<td>6 per 10 000 (Schow et al. 1992)</td>
</tr>
<tr>
<td>Death</td>
<td>7 per 10 000 (Schow et al. 1992)</td>
</tr>
<tr>
<td></td>
<td>Close to zero (Mendelsohn et al. 1995)</td>
</tr>
</tbody>
</table>

Table 3. Complications of percutaneous renal biopsy

Two main technical advances have resulted in safer procedures: the ultrasound guidance and the automated core biopsy system (automated biopsy-gun). Rates of serious complications were as low as <1% in recent series, with an overall risk of kidney function loss of 6 per 10 000 and a mortality risk of 7 per 10 000 (Schow et al., 1992). Nonetheless, complications more commonly reported are transient gross hematuria and hematoma with a frequency ranging between 0% to 6% (Maya & Allon, 2009). A literature review published in 1995 supports the opinion that the risk of catastrophic complications using the actual biopsy methods is close to zero (Mendelsohn & Cole, 1995). These differences observed in
complication rates may result from patient selection, biopsy technique, needle gauge, operator experience and number of needle passes. Despite the fact that percutaneous biopsy can be now considered as a procedure with almost no catastrophic complications if it is performed with standard techniques, it is always associated with minor complications that the attending physician must be aware of. There is obviously a transient damage to the collecting system and to the structures surrounding the kidney. This generates bleeding, creating symptoms such as hematuria and a drop in hemoglobin level (see below). Microscopic hematuria is normally seen in all patients who undergo a kidney biopsy (Altebarmakian et al., 1981), but is generally clinically insignificant and resolves spontaneously within 24 to 48 hours. On the other hand, macroscopic hematuria is seen less frequently, complicating up to 5 to 10% of patients (Marwah & Korbet, 1996). It is also generally clinically insignificant and self resolving in 48 hours. It can be severe, resulting in a significant loss of blood. It should also raise concerns for a concomitant hematoma or arteriovenous fistula, requiring further investigation and monitoring.

Normally, a fall in hemoglobin level is observed after a percutaneous renal biopsy, with a decrease ≥1 g/dL reported in 20.8% of patients in a recent Japanese study (Ishikawa et al., 2009). A perinephric hematoma of more than 2 cm was associated with a significantly greater decrease in Hg level in this study. This drop is usually caused by several factors including local bleeding at the biopsy site (e.g. hematoma, hematuria), hemodilution secondary to hydration with intravenous fluids, recumbency and stimulation of anti-diuretic hormone secretion by pain; and it is not a good predictor of post-biopsy outcome.

Subcapsular perinephric hematoma is certainly more common than previously noted in older retrospective studies where post-procedure sonography was not routinely performed. A recent series of patient showed that hematoma was seen in 33.3% of patients, with a mean surface area of 289.6 mm² (Manno et al., 2004). These hematomas were clinically silent in 90.4% of subjects, with 2.5% complaining of lumbar pain. It appears that there was no association between post-biopsy bleeding and the surface area of the hematoma. Another series reported hematomas in more than 86% of cases, and older studies using computerized tomography (CT) scanning also showed an incidence of 90%, depending on the timing of the evaluation. Furthermore, the clinician must be aware of an extremely rare complication that may be associated with a perinephric hematoma: the laceration of a lumbar artery passing over the lower pole of the kidney (K.T. Kim et al., 1991).

Arteriovenous fistulas are also clinically silent complications of percutaneous renal biopsy. Angiography-based imaging studies reported an incidence of about 10%. The majority (over 90%) resolved spontaneously a year later, requiring no invasive procedure. They rarely become a symptomatic aneurysm that causes high output cardiac failure, hypertension, hematuria and renal failure (by arterial steal). Due to the gravity of the potential complications related to arteriovenous fistulas, they should be monitored with Doppler ultrasound every 3 to 6 months (Korbet et al., 2002).

In summary, there are numerous complications related to percutaneous kidney biopsy ranging from silent hematomas to uncontrolled bleeding with hemorrhagic shock. Clinicians must therefore be aware of these adverse events and investigate rapidly patients who present signs of clinical deterioration. This argues for an overnight observation of the patient after the procedure, with adequate monitoring of his vital signs, degree of hematuria and abdominal pain.
7.1 Predictors of bleeding complications

Determining the predictors of bleeding complications related to percutaneous kidney biopsy has always been a matter of debate in the literature over the last decades, despite the fact that this procedure is routinely and frequently performed worldwide. There are scant prospective data regarding which baseline conditions (e.g. bleeding time, age) can affect significantly the outcomes. A recent Italian prospective study tried to answer this important question (Manno et al., 2004). The authors analyzed baseline characteristics and outcomes of 471 consecutive native kidney percutaneous ultrasound-guided biopsies. Univariate and multivariate analysis of predictors of post-biopsy bleeding complications demonstrated a strong association between post-procedure bleeding and female gender, higher baseline partial thromboplastin time and age, as bleeding tends to occur less in older patients. Surprisingly, no association was made between bleeding time and post-biopsy bleeding. Patients with complications had exactly the same bleeding time than patients without any complications, but all patients with abnormal bleeding time received 8-D-arginine vasopressin (DDAVP), showing afterwards a normalization of their bleeding time prior to biopsy. Only 11 patients had increased bleeding time prior to biopsy, two with moderate von Willebrand factor deficiency and nine with moderate renal failure. Moreover, there was also no impact of the histologic diagnosis on the occurrence of post-biopsy bleeding.

<table>
<thead>
<tr>
<th>Predictors of post-biopsy bleeding</th>
<th>Factors not associated with post-biopsy bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manno et al. 2004</strong></td>
<td><strong>Manno et al. 2004</strong></td>
</tr>
<tr>
<td>Younger age</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>Female gender</td>
<td>Body weight</td>
</tr>
<tr>
<td>Elevated partial thromboplastin</td>
<td>Serum creatinine</td>
</tr>
<tr>
<td>time</td>
<td>Proteinuria</td>
</tr>
<tr>
<td><strong>Ishikawa et al. 2009</strong></td>
<td><strong>Needle gauge</strong></td>
</tr>
<tr>
<td>Perirenal hematoma ≥2.0 cm</td>
<td><strong>Waldo et al. 2009</strong></td>
</tr>
<tr>
<td>assessed immediately after biopsy</td>
<td>Absence of hematoma 1 h post-biopsy</td>
</tr>
<tr>
<td>PT-INR ≥1</td>
<td><strong>Ishikawa et al. 2009</strong></td>
</tr>
<tr>
<td>Mean blood pressure ≥105 mmHg</td>
<td>Age</td>
</tr>
<tr>
<td>Steroid use</td>
<td>Creatinine ≥2.0 mg/dL</td>
</tr>
</tbody>
</table>

Table 4. Predictors of post-biopsy bleeding

A recent retrospective study of 317 patients tried to find predictors of overt bleeding after renal biopsy (Ishikawa et al., 2009). More than 86% of patient presented a perirenal hematoma after biopsy, a majority with a diameter of less than 2 cm. A hematoma ≥2 cm was associated with a greater decrease in hemoglobin levels. The authors determined by multivariate analysis the clinical predictors of bleeding (Hb decrease ≥1.0 g/dL). Perirenal hematoma, prothrombin time-international normalized ratio (PT-INR), mean blood pressure and steroid use were found to be related to overt bleeding (Table 4). Of these factors, perirenal hematoma ≥2cm immediately after the biopsy was the strongest predictor, with a risk of severe anemia increased to about eight times. Post-biopsy ultrasound may therefore be a useful tool to discriminate patients with the highest risk of bleeding complications. However, a recent investigation studying the presence of a hematoma 1 hour post-biopsy as a predictor of major complications was not conclusive (Waldo et al., 2009). The absence of
hematoma was predictive of an uncomplicated post-biopsy evolution, with a negative predictive value of 95%.

7.2 Role of bleeding time in predicting bleeding complications
Utilization of bleeding time prior to the renal biopsy procedure remains controversial. Bleeding time is used frequently by nephrologists before biopsy, mainly for historical reasons, as a predictor of bleeding in spite of no clear evidence supporting its role. On the one hand, a widespread consensus among hematologists supports the fact that it is not a useful predictor of the risk of hemorrhage after a surgical procedure, especially if there is absence of a clinical history of bleeding disorder. Bleeding time could indeed be altered in several conditions including technique variability related to the operator, drugs (e.g. beta-blockers, antibiotics) and various clinical states such as liver disorders and diabetes mellitus (Mattix & Singh, 1999). No study linking the bleeding risk of performing kidney biopsies with abnormal bleeding time has been published. Furthermore, an article describing the position of the College of American Pathologists and the American Society of Clinical Pathologists concluded that bleeding time can be a test useful for testing the response to DDAVP in uremic patients, but it is not a predictor of the bleeding risk in these patients (Peterson et al., 1998).

On the other hand, recent data has shown that prolongation of the bleeding time is not without risk. It was found that the risk of post-biopsy hematoma increased by 21% for each minute of bleeding time prolongation, conferring a two times greater risk of bleeding in patients in which such a rise was seen (Stratta et al., 2007). More recent data demonstrated the same increased risk of major bleeding complications in patients with prolonged bleeding time (Waldo et al., 2009). Moreover, a prospective study of liver biopsies performed without correcting the bleeding time prior to the procedure showed five times higher bleeding complications (Boberg et al., 1999).

DDAVP seems to enhance the release of von Willebrand factor from endothelial cells into plasma. It also increases release of factor VII and adenosine triphosphate by platelets, as well as the uptake of serotonin. Studies have shown a normalization of the bleeding time by DDAVP infusion. Administration of this drug systematically regardless of bleeding time values appears to be cost-ineffective, considering that approximately 80% of patients had normal bleeding times, and it could be related to serious side effects such as hypertension and hyponatremia (Mattix & Singh, 1999; Korbet, 2002). However, a recent randomized controlled trial showed a significant advantage of a systematic DDAVP administration in patients without a significant renal impairment (Manno et al., 2011).

8. Role of percutaneous biopsy in renal tumors
Percutaneous renal biopsies also have a smaller role in the management of renal tumors in adults. Indeed, surgical resection permits a clear pathological diagnosis, as well as generally curing the patient from his/her malignancy. This is based on the fact that carcinomas represent 90% of all renal solid masses in adults when tumor size is greater than 40 mm on imaging studies (Lebret et al., 2007).

Nevertheless, partial or total nephrectomies can be spared for renal masses less than 40 mm in size. A study from a French group showed that renal biopsy prior to surgical resection of a renal mass should be reserved for patients in whom imaging was not able to make an accurate diagnosis (Lebret et al., 2007). It mainly consisted of equivocal lesions that lacked
one or more radiological criteria for malignant lesions, or were less than 40 mm. In this single institution series of 432 patients, 119 percutaneous biopsies were performed in 101 patients. A diagnosis of benign lesions was made in 20% biopsies together with 9 malignant lesions not requiring surgery (lymphoma and metastasis) (Table 5). Thus, 30.4% of patients were not candidates for nephrectomy.

Performing such technique in patients with renal cancer is not without risk. In fact, biopsy tract seeding has been reported in 0.01% of cases in a large series (Smith, 1991, as cited in Lebret et al., 2007). This can be prevented by using coaxial system. In the series described above, no cancer seeding was reported, making percutaneous biopsy a safe procedure in the hands of well-experienced interventional physicians.

<table>
<thead>
<tr>
<th>Histological findings</th>
<th>% of lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant</td>
<td></td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>59</td>
</tr>
<tr>
<td>Transitional cell carcinoma</td>
<td>48</td>
</tr>
<tr>
<td>Metastasis</td>
<td>3</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>7</td>
</tr>
<tr>
<td><strong>Benign</strong></td>
<td></td>
</tr>
<tr>
<td>Oncocytoma</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Angiomyolipoma</td>
<td>20</td>
</tr>
<tr>
<td>Renal abscess/xanthogranulomatous</td>
<td>13</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>4</td>
</tr>
<tr>
<td><strong>Inconclusive</strong></td>
<td></td>
</tr>
<tr>
<td>Normal parenchyma</td>
<td>21</td>
</tr>
<tr>
<td>Necrotic tissue</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Inflammatory tissue</td>
<td>10</td>
</tr>
</tbody>
</table>

Table 5. Histological findings in renal masses (from Lebret et al. 2007)

Despite the fact that surgical resection remains the standard approach for patients with renal tumors, percutaneous biopsy could also be an alternative for particular cases. Fine needle aspiration of a renal mass can also be reserved for patients who would not be able to tolerate surgery, mainly elderly patients, and those with comorbid conditions.

9. Conclusion

Ultrasound-guided percutaneous renal biopsy is a safe procedure with a central role in the diagnosis of parenchymal kidney diseases. Real-time ultrasonography and automated biopsy-gun are the major technical improvements permitting the procedure to be performed with safety and effectiveness. It is accomplished in a hospital setting by well-trained radiologist or nephrologist. With recent technical advances, bleeding complications are quite rare, allowing a shorter observation period (6 to 8 hours) after the procedure in highly selected elective patients.

Areas of uncertainty however still exist. Predictors of bleeding complications are difficult to define clearly. Age, female gender and elevated prothrombin time seem to correlate with an increased risk of post-biopsy bleeding. Ultrasound undertaken immediately after the biopsy procedure can be helpful to determine if the patient is at a risk of bleeding and should be observed for longer period. The role of bleeding time remains controversial to predict overt bleeding mainly due to the fact that no prospective data are available to guide the clinical practice.
Randomized controlled trials would therefore be needed to evaluate certain important questions mainly related to post-procedure bleeding. As approximately 1 to 2 million bleeding time tests are performed annually, it would be interesting to clarify its usefulness as a predictor of post-biopsy bleeding.

10. Acknowledgements

We wish to thank the staff of the Hôpital Maisonneuve-Rosemont radiology department.

11. References


www.intechopen.com
There is no dearth of high-quality books on renal biopsy and pathology in the market. These are either single author or multi-author books, written by world authorities in their respective areas, mostly from the developed world. The vast scholarly potential of authors in the developing countries remains underutilized. Most of the books share the classical monotony of the topics or subjects covered in the book. The current book is a unique adventure in that it bears a truly international outlook and incorporates a variety of topics, which make the book a very interesting project. The authors of the present book hail not only from the developed world, but also many developing countries. The authors belong not only to US but also to Europe as well as to Pakistan and Japan. The scientific content of the book is equally varied, spanning the spectrum of technical issues of biopsy procurement, to pathological examination, to individual disease entities, renal graft pathology, pathophysiology of renal disorders, to practice guidelines.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: